Arcus Biosciences, Inc.
QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
Last updated:
Abstract:
Compounds that inhibit at least one of the A.sub.2A and A.sub.2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A.sub.2A receptor and/or the adenosine A.sub.2B receptor.
Status:
Application
Type:
Utility
Filling date:
3 May 2018
Issue date:
5 Mar 2020